Clinical trials: Myasthenia Gravis Crisis
Myasthenia Gravis, Myasthenia Gravis Crisis
A Prospective Cohort Study Of Myasthenia Gravis
The average annual incidence of Myasthenia gravis is up to (8.0-20.0) / 100,000 people. Myasthenia gravis is an acquired autoimmune disease. All skeletal muscles of patients may be involved.
- Trial name
- NCT04674605
- Testing
- biomarkers
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Myasthenia Gravis, Autoimmune Diseases of the Nervous System
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG.
- Conditions
- Myasthenia Gravis, Autoimmune Diseases of the Nervous System, Neuromuscular Junction Diseases, Thymoma
- Trial name
- NCT05214612
- Testing
- Drug treatment of myasthenia gravis and treatment of crisis
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University